| scholarly article | Q13442814 |
| P50 | author | Amir Zarrinpar | Q51032415 |
| P2093 | author name string | Shankar Subramaniam | |
| Rohit Loomba | |||
| Mano R Maurya | |||
| Shakti Gupta | |||
| Amir Zarrinpar | |||
| P2860 | cites work | Identification of unique microRNA signature associated with lupus nephritis | Q21136392 |
| The microRNA-30 family is required for vertebrate hepatobiliary development | Q24324604 | ||
| Epigenetic differences arise during the lifetime of monozygotic twins | Q24531005 | ||
| SOCS, inflammation, and cancer | Q26991808 | ||
| Silencing of microRNAs in vivo with 'antagomirs' | Q27860891 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults | Q29614911 | ||
| Controversies in the Diagnosis and Management of NAFLD and NASH. | Q30412296 | ||
| MicroRNAs in metabolism and metabolic disorders | Q33612997 | ||
| Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines | Q33865755 | ||
| MicroRNAs in liver disease | Q33880442 | ||
| Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease | Q34009053 | ||
| Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy | Q34021973 | ||
| Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages | Q34146986 | ||
| Circulating microRNAs in patients with non-alcoholic fatty liver disease | Q34179239 | ||
| miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes | Q34186822 | ||
| Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins | Q34572645 | ||
| A twin approach to unraveling epigenetics | Q34713637 | ||
| MicroRNAs and liver disease. | Q34717904 | ||
| Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis | Q34778143 | ||
| Biomarkers of NAFLD progression: a lipidomics approach to an epidemic | Q35120968 | ||
| Heritability of nonalcoholic fatty liver disease | Q36095663 | ||
| Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial | Q36105168 | ||
| Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD | Q36219404 | ||
| Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease | Q36450465 | ||
| Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease | Q36503839 | ||
| Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials | Q36762917 | ||
| MicroRNAs: new regulators of immune cell development and function | Q37223449 | ||
| microRNAs in liver disease: from diagnostics to therapeutics | Q37246198 | ||
| Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study | Q37259603 | ||
| Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection | Q37739949 | ||
| MicroRNAs in development and disease | Q37899669 | ||
| The continuing value of twin studies in the omics era. | Q38030834 | ||
| Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma | Q38128868 | ||
| Noninvasive evaluation of NAFLD. | Q38141711 | ||
| Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma | Q38904799 | ||
| MNT inhibits the migration of human hepatocellular carcinoma SMMC7721 cells | Q39412497 | ||
| Epigenetics: an overview | Q40579140 | ||
| Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis | Q42353353 | ||
| Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. | Q42988522 | ||
| Let-7c microRNA expression and clinical significance in hepatocellular carcinoma | Q43569610 | ||
| Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease | Q43761846 | ||
| The prevalence and etiology of elevated aminotransferase levels in the United States | Q44480010 | ||
| Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest | Q46316392 | ||
| Heritability of mammographic density, a risk factor for breast cancer | Q48611340 | ||
| Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. | Q51442516 | ||
| Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. | Q51786382 | ||
| MicroRNAs in liver disease. | Q51793583 | ||
| Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy | Q60358131 | ||
| IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation | Q84529686 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| liver disease | Q929737 | ||
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 1546-1554 | |
| P577 | publication date | 2015-05-22 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study | |
| P478 | volume | 65 |
| Q96945930 | A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis |
| Q64104335 | A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease |
| Q37173770 | Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis |
| Q38577570 | Caring for children with NAFLD and navigating their care into adulthood |
| Q90151977 | Circulating miRNAs as Novel Diagnostic Biomarkers in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis |
| Q92289897 | Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography |
| Q89304605 | Critical Roles of microRNAs in the Pathogenesis of Fatty Liver: New Advances, Challenges, and Potential Directions |
| Q104555855 | Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review |
| Q46566732 | Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis. |
| Q38668329 | Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice |
| Q92317682 | Differences of microRNA expression profiles between monozygotic twins' blood samples |
| Q90022863 | Differential circulating and visceral fat microRNA expression of non-obese and obese subjects |
| Q90758500 | Downregulated microRNA-130b-5p Prevents Lipid Accumulation and Insulin Resistance in a Murine model of Nonalcoholic Fatty Liver Disease |
| Q44262184 | Editorial: novel association between serum Pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease--authors' reply |
| Q94460975 | Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity |
| Q39358760 | Epigenetics and Liver Fibrosis |
| Q28079271 | Epigenetics in liver disease: from biology to therapeutics |
| Q47623021 | Genetics and epigenetics of NAFLD and NASH: Clinical impact |
| Q45067817 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention |
| Q38806840 | Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease |
| Q30368624 | Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study |
| Q31134971 | Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood |
| Q90234092 | MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial) |
| Q30364476 | Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study. |
| Q36764809 | Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades |
| Q57486401 | MicroRNA profile analysis for discrimination of monozygotic twins using massively parallel sequencing and real-time PCR |
| Q26774294 | MicroRNAs in Nonalcoholic Fatty Liver Disease |
| Q104614316 | MicroRNAs: An Update of Applications in Forensic Science |
| Q104078904 | Neuroprotective effects of miR-331-3p through improved cell viability and inflammatory marker expression: Correlation of serum miR-331-3p levels with diagnosis and severity of Alzheimer's disease |
| Q100393502 | Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches |
| Q90102418 | Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers |
| Q96954178 | Nonalcoholic fatty liver disease and cardiovascular disease phenotypes |
| Q40154653 | Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis |
| Q30366572 | Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. |
| Q52639128 | Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. |
| Q45988395 | Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease. |
| Q45942296 | Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. |
| Q100747560 | Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms |
| Q57067876 | Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease |
| Q90897925 | Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma |
| Q90163452 | Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD |
| Q90644630 | Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease |
| Q47713893 | Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents. |
| Q40528724 | Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study |
| Q40766803 | Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial |
| Q60961391 | miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis |
| Q91127461 | miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis |
Search more.